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ABSTRACT
Background: This study aimed at investigating feasibility of programmed death 
ligand-1 (PD-L1) testing in plasma samples of  advanced NSCLC patients receiving 
first-line treatment, assessing whether circulating (c)PD-L1 levels were modified by 
the therapy and whether baseline cPD-L1 levels were associated with patients’ clinical 
responses and survival outcome.
Methods: Peripheral blood samples were collected from 16 healthy volunteers 
and 56 newly diagnosed NSCLC patients before and at 12th week during the course 
of first-line therapy. The level of PD-L1 was measured in plasma samples using the 
human (PD-L1/CD274) ELISA kit (CUSABIO, MD, USA). The Mann Whitney test or 
Fisher’s test were used for comparisons. Survival analysis was performed using 
Kaplan Meyer method, providing median and p-value.
Results: Baseline median cPD-L1 was 42.21 pg/ml (range 12.00-143.49) 
in NSCLC patients and 37.81 pg/ml (range 9.73-90.21) in healthy control cohort  
(p = 0.78). Median cPD-L1 increased in patients treated with first-line chemotherapy 
(63.20 pg/ml vs 39.34 pg/ml; p = 0.002), with no changes in patients exposed to non-
chemotherapy drugs (42.39 pg/ml vs 50.67 pg/ml; p = 0.398). Time to progression 
and overall survival were 4.4 vs 6.9 months (p = 0.062) and 8.8 vs 9.3 months  
(p = 0.216) in cPD-L1 positive vs cPD-L1 negative patients. Baseline cPD-L1 levels 
increased with the ascending number of metastatic sites, even if the association was 
not statistically significant (p = 0.063).
Conclusions: This study showed that cPD-L1 testing is feasible, with chemotherapy 
influencing PD-L1 plasma levels. The possibility of using such test for predicting 
or monitoring the effect of immunotherapy or combination of chemotherapy and 
immunotherapy warrant further investigations.
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INTRODUCTION
A deeper understanding of the molecular basis 
of tumor immunogenicity and cancer immune-escape 
favored the development of a new class of drugs which 
are able to modulate the anti-tumor immune response 
[1, 2], ultimately leading to an impressive and durable 
clinical benefit in a significant subgroup of patients 
with advanced non-small cell lung cancer (NSCLC). 
Particularly to date we have three monoclonal antibodies 
(MoAbs), Nivolumab, Pembrolizumab and Atezolizumab, 
targeting the programmed cell death 1 (PD1)/programmed 
cell death 1 ligand (PD-L1) immune-checkpoint, approved 
by regulatory authorities for the treatment of advanced 
NSCLC [3]. Overall, four phase III randomized studies 
demonstrated that PD1/PD-L1 inhibitors are more 
effective and better tolerated than the second-line single 
agent chemotherapy [4–7], thus representing the new 
standard of care for NSCLC patients who experienced 
progression after platinum-combinations. A recent survival 
update of the CheckMate-003 phase I study revealed that 
about 15% of NSCLC patients were still alive after 5 years 
of therapy with nivolumab [8], thus suggesting that these 
drugs could offer the potential for a durable disease control 
and long-term survival in a subset of patients. Conversely, 
about 50% of pre-treated patients do not gain any benefit 
from immunetherapy [4–7], and a small subgroup of them 
develop “hyperprogression” or early death within the first 
3 months of therapy with checkpoint inhibitors (ICIs) [9–
11], making the identification of predictive biomarkers an 
urgent challenge for translational lung cancer research. The 
majority of studies including pre-treated NSCLC patients 
showed that the benefit of ICIs increased accordingly to 
the tumor PDL1-expression. However patients with PDL1 
negative tumors also benefited from checkpoint inhibitors 
as compared to standard chemotherapy with docetaxel 
[4–7], suggesting that, because of its low sensitivity and 
specificity, PDL1 status alone may not be considered as an 
appropriate biomarker to exclude pre-treated patients from 
immunotherapy. Recently, Pembrolizumab revealed a 
significant superiority over platinum based chemotherapy 
as first-line treatment of non-oncogene addicted NSCLC 
patients whose tumors overexpressed PD-L1>50% 
[12], becoming the new backbone in this subgroup of 
patients who represent about 30% of the overall untreated 
population. In addition, recent studies showed that ICIs 
are effective in first-line setting irrespective of PD-L1 
expression when used in combination with chemotherapy 
[13]. In light of these evidences, the PD-L1 testing has 
been incorporated within the international guidelines 
and it is now recommended together with the molecular 
testing for all patients with newly diagnosed advanced 
NSCLC, in order to ensure the most effective upfront 
treatment for each patient [3]. Even if limited by a lack of 
standardization in testing methods, the PD-L1 assessment 
by immune-histochemistry (IHC) on tumor tissue 
represents the current gold standard. However it’s not 
applicable in those patients whose tissue is not available 
at the time of diagnosis or tissue analysis results are not 
evaluable. Furthermore a biopsy sample is just a snapshot 
of the tumor not reflecting the overall microenvironment, 
and thus subjected to the intra-tumor heterogeneity. In 
addition, the immune response is a very complex and 
dynamic process taking place in different sites other 
than tumor-microenvironment, suggesting that the PD-
L1 evaluation on tumor site could be not completely 
representative of the overall individual immune status. 
In the last decade an alternative not invasive approach, 
known as liquid biopsy, has been proposed to overcome all 
the aforementioned issues [14]. Epidermal growth factor 
receptor (EGFR) mutational testing by circulating tumor 
(ct) DNA analysis demonstrated an adequate diagnostic 
accuracy [15–18] and has been recently incorporated in 
the clinical management of all EGFR-mutated NSCLC 
patients who progressed after first-generation EGFR 
tyrosine kinase inhibitors (TKIs) and in a subgroup of 
patients with newly diagnosed metastatic disease who 
cannot undergo tumor biopsy or received uninformative 
results from tissue molecular analysis [3]. Even if the 
modulation of immune-system is a more complex and 
highly regulated process, however the identification and 
validation of potential biomarkers in the blood of patients 
could offer a valid tool in the hands of oncologists to 
easily monitor the efficacy of ICIs therapy. In the current 
study we aim to evaluate the feasibility of PD-L1 testing 
in the plasma of advanced NSCLC patients and to assess 
if circulating (c) PD-L1 levels may be modified by first-
line therapies and are correlated with patients’ outcomes.
RESULTS
Patients’ characteristics and cPD-L1 detection
From January 2013 to November 2015 a total of 
56 patients with histologically or citologically confirmed 
diagnosis of advanced NSCLC who were candidate to 
receive first-line therapy and 16 healthy volunteers were 
included in the study. Median age was 70 years (range 48-
85) and the majority were males and exhibited an Eastern 
Cooperative Oncology Group (ECOG) performance status 
score of 0 as reported in Table 1. The majority of patients 
were former smokers (57.1%) with adenocarcinoma 
histology (78.6%). Molecular alterations including 
KRAS mutations, EGFR mutations, and ALK/ROS1 re-
arrangements were detected in 23.2%, 19.6%, and 5.4% 
of analyzed tumor samples, respectively. Chemotherapy 
represented the first line treatment in 41 out of 56 
(73.2%) patients, while 12 (21.4%) patients received 
targeted therapies including EGFR-TKIs (gefitinib N = 4, 
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erlotinib N = 3, dacomitinib N = 2) and ALK/ROS1-TKIs 
(crizotinib, N = 3) and only 3 (5.4%) patients received 
immunotherapy with nivolumab within a clinical trial. 
Median PD-L1 plasma level at baseline was 42.21 pg/
Table 1: Patients’ characteristics
Characteristic Total (n) %
Total number of patients 56 100
Median age (years–range) 70 48–85
Gender
Male
Female
38
18
67.9
32.1
Histology
Adenocarcinoma
Squamous-cell carcinoma
Not specified
44
6
6
78.6
10.7
10.7
Smoking history
Never
Former 
Current
11
32
13
19.6
57.1
23.2
Performance status
0
1
2
3
38
10
6
2
67.8
17.9
10.7
3.6
Number of metastaticsites
1–2
3–4
≥5
20
31
5
35.7
55.4
8.9
First line treatment
Chemotherapy
Targeted therapies
Immunotherapy
41
12
3
73.2
21.4
5.4
EGFR status
Mutateda
Wild type
Unknown
11
37
8
19.6
66.1
14.3
KRAS status
Mutatedb
Wild type
Unknown
13
25
18
23.2
44.7
32.1
ALK status
Rearranged
Wild type
Unknown
2
37
17
3.6
66.1
30.3
ROS1 status
Rearranged
Wild type
Unknown
1
18
37
1.8
32.1
66.1
Triple negativec 9 16.1
aEGFR mutations included:  exon 18 = 1 (9.0%); exon 19 = 4 (36.4%);  exon 20 = 2(18.2%); exon 21 = 4 (36.4%); b KRAS mutations 
included: codon 12 = 13(100%); cTriple negative included EGFR/KRAS/ALK/ROS1 wild-type patients.
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ml (range 12.00-143.49) in NSCLC patients, thus not 
significantly higher than that observed in the healthy 
control cohort (37.81 pg/ml, range 9.73-90.21; p = 0.78). 
Considering as cut-off value the median PD-L1 plasma 
level of 37.81 pg/ml detected in the healthy patients 
cohort, patients were classified as “cPD-L1 positive” 
(median plasma PD-L1>37.81 pg/ml; N = 32, 57.1%) or 
“cPD-L1 negative (median plasma PDL1<37.81 pg/ml; 
N = 24, 42.9%). As reported in Table 2, no significant 
association was observed between cPD-L1 levels and 
patients’ characteristics. A trend toward an increase of 
cPD-L1 according to the number of metastatic sites has 
been reported, even if it was not statistically significant 
(p = 0.063, Figure 1). 
Effect of treatments on cPD-L1 levels 
In 25 out of 56 patients evaluable after 3 months 
of first-line therapy, median PD-L1 plasma levels 
significantly increased as compared to baseline median 
value (58.63 pg/mL, p = 0.04). Among 18/41 patients 
treated with first-line chemotherapy-regimens and 
evaluable after 3 months, we observed a significant 
increase of the median cPD-L1 (63.20 pg/ml (range 24.65 
– 165.65) versus 39.34 pg/ml (range 20.05 – 143.49), p = 
0.002). Conversely, among 7/12 patients treated with no-
chemotherapy agents (dacomitinib N = 2, gefitinib N = 
2, erlotinib N = 1, nivolumab N = 2) and evaluable after 
3 months, not significant changes in median cPD-L1 has 
been observed (42.39 pg/ml (range 14.31 – 114.76) vs 
50.67 pg/ml (range 13.66 – 65.95), p = 0.398) (Figure 2).
cPD-L1 level and tumor response
After 3 months of first-line treatment, 47 of 56 
(83.9%) NSCLC patients were evaluable for tumor 
response. Among them, one patient (2.1%) experienced 
complete response (CR), 20 (42.5%) had a partial response 
Table 2: Correlation between plasma PD-L1 levels and patients’ characteristics
Patients characteristic
PD-L1 classes (based on medianvalue) - N (%)
p value
negative positive
Age 
≤70.4
>70.4
13 (46.4)
11 (39.3)
15 (53.6)
17 (60.7)
0.58
Gender
Male
Female
16 (42.1)
8 (44.4)
22 (57.9)
10 (55.6)
0.86
Smoking history
Never/Former 
Current
19 (44.2)
5 (38.5)
24 (55.8) 
8 (61.5)
0.71
Number of metastaticsites
1
2
3
4
5
6
2 (50.0)
8 (50.0)
11 (47.8)
2 (25.0)
1 (33.3)
0 (0.0)
2 (50.0)
8 (50.0)
12 (52.2)
6 (75.0)
2 (66.7)
2 (100.0)
0.06
EGFR status
Mutateda
Wild type
5 (45.5)
17 (45.9)
6 (54.5)
20 (54.1)
0.97
KRAS status
Mutatedb
Wild type
5 (38.5)
13 (52.0)
8 (61.5)
12 (48.0)
0.42
ALK status
Rearranged
Wild type
1 (50.0)
15 (40.5)
1 (50.0)
22 (59.5)
0.79
ROS1 status
Rearranged
Wild type
1 (100.0)
6 (33.3)
0 (0.0)
12 (66.7)
0.36
aEGFR mutations included:  exon 18 = 1 (9.0%); exon 19 = 4 (36.4%);  exon 20 = 2 (18.2%); exon 21 = 4 (36.4%); b KRAS 
mutations included: codon 12 = 13 (100%).
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(PR), 19 (40.4%) stable disease (SD), and 7 (14.9%) 
progression disease (PD). No significant differences in 
overall response rates (ORR: CR+PR) have been observed 
between cPDL1 positive and cPDL1 negative patients in 
the overall NSCLC population (ORR: 43.5% vs 45.8%; 
p = 0.87), in patients treated with chemotherapy-regimens 
(ORR: 47.1% vs 40%, p = 0.735), and in patients treated 
with no chemotherapy regimens (ORR: 33.3% vs 55.6%; 
p = 0.608), as illustrated in Table 3.
cPD-L1 level and patients’ survival outcomes
At a median follow-up time of 14.7 months (range 
2–36), disease progression occurred in 41 patients, while 
36 patients died because of tumor progression, and 20 
patients were still alive at the time of data analysis. Median 
time to progression (TTP) was 5.6 months and median 
overall survival (OS) was 8.8 months in the overall NSCLC 
population. As showed in Figure 3, no difference in TTP 
nor in OS were observed in cPD-L1 positive as compared 
to cPD-L1 negative patients (TTP: 4.4 versus 6.9 months, 
p = 0.062; OS: 8.8 versus 9.3 months, p = 0.216). No 
differences in TTP nor in OS were observed between cPD-L1 
positive and negative subgroups even when the analysis was 
restricted to patients treated with chemotherapy (TTP: 3.3 
versus 5.6 months, p = 0.623; OS: 4.1 versus 6.8 months, p = 
0.322) or no chemotherapy-regimens (TTP: 4.6 versus 15.9 
months, p = 0.188; OS: 9.7 versus 17.4 months, p = 0.887).
DISCUSSION
This proof-of concept study demonstrated the 
feasibility of PD-L1 testing in plasma samples of patients 
with advanced NSCLC, showing that the cPD-L1 
expression levels may be significantly modified by the 
standard first-line chemotherapy. As tumor tissue PDL1 
assessment by IHC is currently recommended by all the 
international guidelines as diagnostic test for patients 
with advanced NSCLC who are candidate to receive 
upfront treatment [3], the possibility to detect and monitor 
PDL1 expression in the plasma before and during the 
course of therapies could play an important role in the 
management of NSCLC patients, especially when tissue 
is not available at the time of diagnosis or tissue analysis 
results are not evaluable. Particularly, monitoring the 
cPDL1 level changes during first-line treatment revealed 
opposite trends in predefined subsets of patients. Indeed 
the results of our analysis showed that the median cPDL1 
levels significantly increased (63.20 pg/ml vs 39.34 pg/ml, 
p = 0.002) in patients receiving first-line chemotherapy, 
providing a potential biological explanation to the efficacy 
of immunotherapy plus chemotherapy combinations even 
in the subgroup of patients with PD-L1 negative tumors 
at baseline IHC assessment [13]. Conversely in the small 
subgroup of patients treated with non-chemotherapy 
agents, largely represented by EGFR-mutated patients, the 
high median baseline PD-L1 value decreased (42.39 pg/ml 
vs 50.67 pg/ml, p = 0.398) during EGFR-TKI treatment. 
These data are in line with recent evidences showing that 
PD-L1 is constitutively expressed by EGFR-mutated 
tumors and is subjected to decrease after EGFR-TKIs 
[19–21], thus making these patients less responsiveness 
to subsequent anti-PD1 therapies. Furthermore we 
know that although the high level of PD-L1 expression, 
oncogene-addicted NSCLC are associated with a very 
low tumor mutational burden [22] and a non-inflamed 
tumor microenvironment, and are characterized by 
neither an immune response nor a T-cell tumor infiltration 
Figure 1: Baseline PD-L1 plasma levels according to the number of metastatic sites.
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[19, 23],  thus less likely to respond to immunotherapy 
[23, 24]. Our findings demonstrated that cPDL1 expression 
levels may be significantly modified by the patients’ 
anticancer treatments. As compared to the archival tumor 
biopsy, the longitudinal monitoring of cPDL1 levels in the 
plasma of NSCLC patients would allow to easily identify 
any significant variations during the course of therapies 
which can inform oncologists about treatment decisions in 
everyday practice. Furthermore several evidences revealed 
that PDL1 is an heterogeneous and dynamic biomarkers, 
subjected to both space and time variability [25]. Thus a 
single tumor biopsy could not reflect neither the overall 
tumor microenvironment nor the systemic immune 
response in different individuals [26]. In this regards the 
evaluation of cPDL1 in the plasma of NSCLC patients 
could be more representative of the overall immune 
status at single patient level in a determinate time-point 
of the disease course supporting the oncologists in their 
clinical decisions. Pre-clinical data showed that only PD-
L1 positive, but not PD-L1 negative cell lines secreted 
cPD-L1 in their supernatant [27], suggesting that the 
cPD-L1 could derive from the cell surface protein through 
different mechanisms including proteolytic cleavage 
or alternative mRNA splicing. However the source of 
cPD-L1 remains uncertain and these preliminary data 
need to be proven in clinical setting. In addition to that, 
the results of our study showed an interesting trend toward 
a not significant increase of cPD-L1 levels according to 
the number of metastatic sites in the included population. 
As reported in previous studies [28], this association could 
be the result of a greater release of tumor DNA into the 
blood of patients with high tumor burden, suggesting that 
the extension of the disease could significantly influence 
our ability to detect PD-L1 in the plasma of patients with 
advanced NSCLC. This has been already demonstrated for 
EGFR-mutations detection by ctDNA analysis [29–31] in 
EGFR-positive NSCLC patients but need to be further 
investigated for cPD-L1 and other potential biomarkers 
Table 3: Tumor response rate in NSCLC patients
Type of treatment PD-L1 status 
ORR-N (%)
p-value
CR + PR SD + PD
All treatment PD-L1 positive
  PD-L1 negative
10 (43.5)
11 (45.8)
13 (56.5)
13 (54.2) 0.87
Chemotherapy PD-L1 positive
  PD-L1 negative
8 (47.1)
6 (40.0)
9 (52.9)
9 (60.0) 0.73
No chemotherapy PD-L1 positive
  PD-L1 negative
2 (33.3)
5 (55.6)
4 (66.7)
4 (44.4) 0.60
ORR = overall response rate; CR = complete response; PR = partial response; SD = stable disease; PD = progression 
disease.
Figure 2: PD-L1 plasma levels at baseline (A) and after 3 months of first-line treatment (B) in subgroup of patients receiving chemotherapy 
(red) or no chemotherapy (blue) agents. 
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detected in the blood of NSCLC patients receiving 
ICIs. Finally some limiting factors of this study need to 
be mentioned, including the low number of evaluated 
patients, the short follow-up, the heterogeneity of both 
tumors’ molecular profile and treatment regimens, and the 
lack of a tumor tissue analysis as reference test because 
of the unavailability of sufficient archival tissue for PD-
L1 expression assessment. Thus it remains still unknown 
the relationship between cPD-L1 levels and tumor tissue 
PD-L1 expression or other peripheral blood parameters 
associated with systemic inflammatory state such as 
neutrophil-lymphocytes ratio. It would be interesting also 
to monitor the cPDL-1 levels beyond 12 weeks in order 
to investigate any significant modifications in NSCLC 
patients who respond to immunotherapy or chemo-
immunotherapy combinations.
In conclusion the results of this study demonstrated 
that PDL1 testing in the plasma of advanced NSCLC 
patients is feasible and cPDL1 levels significantly increase 
during first-line chemotherapy. These data suggest 
cPD-L1 as a potential biomarker in the early prediction 
and real-time monitoring of both immunotherapy and 
chemo-immune combinations efficacy, warranting further 
investigations in prospective clinical studies including 
larger cohort of patients and longer follow-up. A dynamic 
assessment of cPD-L1 in association with other emerging 
biomarkers could allow a better patients’ stratification 
favoring the development of personalized immune-
treatment strategies.
MATERIALS AND METHODS
Patients 
Patients were eligible if they had histologically or 
cytologically confirmed diagnosis of non- squamous or 
squamous NSCLC, stage IV (according to Version 8th of 
the International Association for the Study of Lung Cancer 
(IASLC) TNM Staging System), Eastern Cooperative 
Oncology Group (ECOG) performance-status score <3, 
and had not previously received any systemic treatment 
for advanced/metastatic disease.   
A cohort of healthy volunteers (individuals who 
were not affected by oncological, autoimmune, metabolic 
and infectious diseases), was also included in the study for 
plasma PD-L1 assessment, and the results obtained were 
compared with those observed in NSCLC patients.
The study was conducted in accordance with the 
International Conference on Harmonization Guidelines on 
Good Clinical Practice and the Declaration of Helsinki.
The trial protocol was previously approved by the local 
Independent Ethics Committee and both the cancer 
patients and the healthy volunteers provided a written 
informed consent before enrollment. 
Study design and treatment
From January 2013 to November 2015 eligible 
patients were included in thisprospective cohort study and 
received first-line standard systemic treatment according 
to their tumors’ histology and molecular profile. All the 
treatments were continued until disease progression or 
the occurrence of an unacceptable level of toxicity, or the 
completion of permitted cycles (up to 4-6 for platinum-
based chemotherapies). Mainteinance  treatment with 
single agent pemetrexed was allowed for patients with 
non-squamous NSCLC who had not progression after 
4 cycles of chemotherapy with platinum-pemetrexed. 
Radiological evaluation of treatment efficacy by CT-scan 
was performed after 12 weeks of therapy and responses 
were evaluated by Response Evaluation Criteria in Solid 
Tumors (RECIST)version 1.1. 
Figure 3: Kaplan-Meier analysis of time to progression (TTP) (A) and overall survival (OS) (B) in NSCLC patients according to the 
baseline cPD-L1 status.
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Objectives of the Study
The main objective of the study was to evaluate 
the feasibility of PD-L1 testing in plasma samples of 
patients with advanced NSCLC and to determine how the 
expression levels of cPD-L1 might be modified by the 
standard first-line treatment.
Secondary objective of the study was to investigate 
the relationship between the plasma cPD-L1 levels 
of NSCLC patients, their clinical characteristics and 
treatment efficacy outcomes, including ORR, TTP and OS.
Circulating  PD-L1 assessment 
Peripheral blood samples were collected 
frompatients included in the study before and at 12th 
weeks during the course of first-line therapy, according 
to a simple and standardized protocol and stored frozen 
as 500 ml aliquots at –80° C. The expression levels of 
PD-L1 were assessed in plasma samples using the Human 
programmed death ligand-1 (PD-L1/CD274) ELISA kit 
(CUSABIO, MD, USA). Plasma samples were centrifuged 
for 15 minutes at 1000 × g and the assay was performed 
according to the manufacturer’s instructions. Briefly, 96-
well plates were incubated with standards and plasma 
samples for 2 hours at 37° C. Then, a biotin-conjugated 
antibody specific for PD-L1 was added to each well. After 
several aspiration/wash processes, horseradish peroxidase 
(HRP)-conjugated avidin was added. After incubation with 
a substrate solution, samples absorbance was read at 450 
nm with the IMarkMicroplate Absorbance Reader (Biorad, 
Italy). The concentrations of PD-L1 were calculated 
according to standard curves.
Statistical analysis
The median PD-L1 plasma levels were calculated 
in healthy volunteers, and in NSCLC patients before 
and after 12 weeks of therapy. The Mann Whitney test 
was used for intergroup comparisons of two independent 
samples while Fisher’s test was used  for categorical 
values.
Paired Wilcoxon test was used to compare median 
PD-L1 before and after first line therapy. For efficacy 
analysis, patients were grouped according to their plasma 
PD-L1 concentration into “positive” if they had plasma 
PD-L1 concentration higher than median PD-L1 value 
observed in the healthy population or “negative” if they 
had plasma PD-L1 concentration below the median PD-
L1 valueobserved in the healthy population. Patients’ 
clinical-pathological characteristics and associations with 
plasma PD-L1 level were examined with a descriptive 
analysis comparing the differences by χ2 test or Fisher’s 
exact test as appropriate. A p-value < 0.05 was considered 
significant.
Efficacy outcomes, including ORR, TTP and OS 
defined as the time between the date of inclusion and the 
date of disease progression or death, respectively, were 
assessed in cPDL1 positive vs cPDL1 negative patients 
both in the overall cancer population and in pre-defined 
subgroups of patients.
Survival analysis was performed using Kaplan 
Meyer method, providing median and p-values, with 
the use of the logrank test for comparisons. A p-value < 
0.05 was used as threshold for statistical significance. 
All the statistical analysis were performed using SPSS 
Statisticssoftware version 20 (IBM, Armonk, New York, 
USA).
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